Category: Medical Device News
-
How digital twins are pioneering a new era of personalized, longitudinal healthcare
Dr. Amanda Randles explains how they are developing digital twins to move medicine beyond static snapshots to dynamic, personalized care.
-
Seamflow secures $4.5m to deploy AI for testing and certification bottlenecks
London-based AI startup raises seed funding to tackle certification delays in medical devices and industrial sectors.
-
RevealDx wins FDA clearance for lung nodule assessment software
New AI software aims to help radiologists assess lung nodule cancer risk and improve early detection.
-
How ambient AI is capturing healthcare’s unheard data
The Sciensus team discusses how ambient AI captures patient sentiment to augment nurses, personalise care, and help keep patients healthier at home.
-
Hospital of 2026: Local LLMs and AI Are Redefining Healthcare
myTomorrow’s Danny den Hamer identifies two trends for 2026: hospitals adopting local AI/trusted partners, and a rise in certified AI medical devices.
-
The New Gold Rush: High-stakes race for multi-cancer blood tests
Abbott’s $23 billion Exact Sciences buyout sets stage for high-stakes MCED battle, Elena Meng talks about the major players in the sector and hurdles.
-
Stereotaxis MAGiC catheter cleared by FDA for robotic heart ablation
The US FDA approves Stereotaxis’ robotic magnetic navigation catheter for complex cardiac arrhythmia procedures.
-
SABCS25: Agendia’s genomic testing guides breast cancer care
Agendia’s VP of clinical development notes that new FLEX study data show genomic signatures predict chemotherapy benefit, improving personalized treatment for early breast cancer.
-
HeartBeam’s stock shows strong pulse after FDA clearance
A cable-free, credit-card sized ECG device for at-home heart monitoring receives regulatory approval, paving the way for a 2026 launch.
Latest posts
-
ASH25: Gallop’s LYT-200 shows unprecedented survival in AML
The company’s execs talk about the striking efficacy and safety signals seen in Phase I data, the science behind the molecule, and their vision for transforming AML therapy.
-
Novo Nordisk’s denecimig cuts bleeding in hemophilia A regardless of inhibitors
Phase III trial shows once‑monthly and once‑weekly denecimig (Mim8) significantly reduces annualized bleeding rate versus standard care, with up to 95% of patients bleed‑free.
-
Beyond the Snapshot: Continuous physiologic monitoring in clinical trials
Vivalink’s CEO discusses how continuous physiologic monitoring is transitioning from a niche tool for early-stage feasibility studies to a core component of late-stage drug development.











